CompletedPhase 3NCT03921541
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
Studying Argininemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aeglea Biotherapeutics
- Principal Investigator
- Cortney Caudill, LCSWAeglea BioTherapeutics, Inc.
- Intervention
- Pegzilarginase(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2019 – 2023
Study locations (30)
- Harvey Pediatrics, Rogers, Arkansas, United States
- Children's Hospital of Orange County, Orange, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida College of Medicine, Gainesville, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Cohen Children's Medical Center (Northwell Health), Queens, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- University of Texas Health Science Center Medical School at Houston, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03921541 on ClinicalTrials.gov